Brief: UCB Says Bimekizumab Data In Plaque Psoriasis At EADV Showed Four-Year Sustained Remission

UCB SA

17/09/2025 06:17

Sept 17 (Reuters) - Ucb SA UCB.BR:

BIMEKIZUMAB DATA IN MODERATE-TO-SEVERE PLAQUE PSORIASIS AT EADV SHOWED FOUR-YEAR SUSTAINED REMISSION, AND POTENTIAL TO REDUCE PSORIATIC ARTHRITIS PROGRESSION RISK

HIGH RESPONSES MAINTAINED OVER FOUR YEARS IN NEARLY HALF OF PATIENTS

THREE- AND FOUR-YEAR DATA FROM ACROSS THEIR PHASE 3 TRIALS FOR BIMZELX® (BIMEKIZUMAB) IN MODERATE-TO-SEVERE PLAQUE PSORIASIS

Source text: [ID:]

Further company coverage: UCB.BR

 (Gdansk Newsroom)

 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))